Inflammatory and anti-glioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L): Treatment with hsFlt3L inhibits intracranial glioma progression

Molecular Therapy

Volumn 10, Issue 6, 2004, Pages 1071-1084

  Ali, Sumia ^a,b,c,d   Curtin, James F ^a,d   Zirger, Jeffrey M ^a,d   Xiong, Weidong ^a,d   King, Gwendalyn D ^a,d   Barcia, Carlos ^a,d   Liu, Chunyan ^a,d   Puntel, Mariana ^a,d   Goverdhana, Shyam ^a,d   Lowenstein, Pedro R ^a,b,d   Castro, Maria G ^a,b,d  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adenovirus; Brain; Flt3L; HSV1 TK; Immunology; Tumor

Indexed keywords

ADENOVIRUS VECTOR; CD4 ANTIGEN; CD8 ANTIGEN; FLT3 LIGAND; GLYCOPROTEIN P 15095; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; BRAIN TISSUE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; GLIOMA; GROWTH INHIBITION; LIFESPAN; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; CRANIAL NERVE NEOPLASMS; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GLIOMA; HUMANS; INFLAMMATION; MALE; MEMBRANE PROTEINS; MICE; NEOPLASM TRANSPLANTATION; RATS; SOLUBILITY; SURVIVAL RATE; TIME FACTORS;

ADENOVIRIDAE; ANIMALIA;

EID: 10344265483     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.08.025     Document Type: Article

References (53)

1. M.G. Castro et al. Current and future strategies for the treatment of malignant brain tumors Pharmacol. Ther. 98 2003 71-108
2. A. Puumalainen et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses Hum. Gene Ther. 9 1998 1769-1774
3. A.M. Sandmair et al. Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses Hum. Gene Ther. 11 2000 2197-2205
4. L.M. Liau et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens J. Neurosurg. 90 1999 1115-1124
5. D.E. Post G. Fulci E.A. Chiocca E.G. VanMeir Replicative oncolytic herpes simplex viruses in combination cancer therapies Curr. Gene Ther. 4 2004 41-51
6. G. Fulci E.A. Chiocca Oncolytic viruses for the therapy of brain tumors and other solid malignancies: A review Front. Biosci. 1 2003 346-360
7. M. Ehtesham et al. Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4 Neoplasia 6 2004 287-293
8. J.S. Yu G. Liu H. Ying W.H. Yong K.L. Black C.J. Wheeler Vaccination with tumor lysate-pulsed dendritic cells elicits antigen specific cytotoxic T-cells in patients with malignant glioma Cancer Res. 64 2003 4973-4979
9. M. Izquierdo et al. Human malignant brain tumor response to herpes simplex thymidine kinase (HSVtk)/ganciclovir gene therapy Gene Ther. 3 1996 491-495
10. Z. Ram et al. Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells Nat. Med. 3 1997 1354-1361
11. T.W. Trask et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors Mol. Ther. 1 2000 195-203
12. J.M. Markert et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial Gene Ther. 7 2000 867-874
13. R. Rampling et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther. 7 2000
14. E.C. Holland Gliomagenesis: Genetic alterations and mouse models Nat. Rev. Genet. 2 2001 120-129
15. E. Maraskovsky et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified J. Exp. Med. 184 1996 1953-1962
16. B. Pulendran et al. Developmental pathways of dendritic cells in vivo: distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice J. Immunol. 159 1997 2222-2231
17. J.M. Serot B. Foliguet M.C. Bene G.C. Faure Ultrastructural and immunohistological evidence for dendritic-like cells within human choroid plexus epithelium Neuroreport 8 1997 1995-1998
18. P.R. Lowenstein Dendritic cells and immune responses in the central nervous system Trends Immunol. 23 2002 70
19. C.A. Kruse M.C. Molleston E.P. Parks P.M. Schiltz B.K. Kleinschmidt-DeMasters W.F. Hickey A rat glioma model, CNS-1, with invasive characteristics similar to those of human gliomas: A comparison to 9L gliosarcoma J. Neurooncol. 22 1994 191-200
20. R.A. Dewey et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials Nat. Med. 5 1999 1256-1263
21. C. Cowsill et al. Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: Reduced cytotoxicity of a truncated HSV1-TK Gene Ther. 7 2000 679-685
22. A. Bigliari et al. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model Mol. Ther. 2004 (in press)
23. P.R. Lowenstein Immunology of viral-vector-mediated gene transfer into the brain: An evolutionary and developmental perspective Trends Immunol. 23 2002 23-30
24. B. Serafini S. Columba-Cabezas F. Di Rosa F. Aloisi Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis Am. J. Pathol. 157 2000 1991-2002
25. B. Serafini B. Rosicarelli R. Magliozzi E. Stigliano F. Aloisi Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis Brain Pathol. 14 2004 164-174
26. F. Aloisi F. Ria L. Adorini Regulation of T-cell responses by CNS antigen-presenting cells: Different roles for microglia and astrocytes Immunol. Today 21 2000 141-147
27. H.G. Fischer G. Reichmann Brain dendritic cells and macrophages/microglia in central nervous system inflammation J. Immunol. 166 2001 2717-2726
28. H.G. Fischer U. Bonifas G. Reichmann Phenotype and functions of brain dendritic cells emerging during chronic infection of mice with Toxoplasma gondii J. Immunol. 164 2000 4826-4834
29. T. Suter et al. The brain as an immune privileged site: Dendritic cells of the central nervous system inhibit T cell activation Eur. J. Immunol. 33 2003 2998-3006
30. P. Kivisakk et al. Expression of CCR7 in multiple sclerosis: implications for CNS immunity Ann. Neurol. 55 2004 627-638
31. M. Pashenkov N. Teleshova H. Link Inflammation in the central nervous system: The role for dendritic cells Brain Pathol. 13 2003 23-33
32. P.G. Stevenson J.M. Austyn S. Hawke Uncoupling of virus-induced inflammation and anti-viral immunity in the brain parenchyma J. Gen. Virol. 83 2002 1735-1743
33. +T cells into the central nervous system by professional antigen-presenting cells Am. J. Pathol. 154 1999 481-494
34. M.K. Matyszak V.H. Perry The potential role of dendritic cells in immune-mediated inflammatory diseases in the central nervous system Neuroscience 74 1996 599-608
35. J.M. Sroga T.B. Jones K.A. Kigerl V.M. McGaughy P.G. Popovich Rats and mice exhibit distinct inflammatory reactions after spinal cord injury J. Comp. Neurol. 462 2003 223-240
36. J.M. Zirger et al. Immune system regulation of transgene expression in the brain. 2. Differential increase of mRNAs encoding for interferon-regulated, chemokine, and T-cell genes during either innate acute or chronic systemic adaptive immune responses to first generation adenoviral viral vectors Mol. Ther. 9 Suppl. 1 2004 1019
37. C. Barcia et al. Immune system regulation of transgene expression in the brain. 1. Systemically activated immune responses silence adenoviral vector-encoded transgene expression in the brain through both noncytolytic and cytotoxic mechanisms Mol. Ther. 9 Suppl. 1 2004 459
38. N.C. Fernandez et al. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo Nat. Med. 5 1999 405-411
39. D.H. Lynch A. Andreasen E. Maraskovsky J. Whitmore R.E. Miller J.C. Schuh Flt3 ligand induces tumor regression and antitumor immune responses in vivo Nat. Med. 3 1997 625-631
40. D.H. Lynch Induction of dendritic cells (DC) by Flt3 Ligand (FL) promotes the generation of tumor-specific immune responses in vivo Crit. Rev. Immunol. 18 1998 99-107
41. G.P. Dunn A.T. Bruce H. Ikeda L.J. Old R.D. Schreiber Cancer immunoediting: From immunosurveillance to tumor escape Nat. Immunol. 3 2002 991-998
42. S. Mukherjee et al. The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor Cancer Gene Ther. 8 2001 580-588
43. G.W. Wilkinson A. Akrigg Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector Nucleic Acids Res. 20 1992 2233-2239
44. A.F. Shering et al. Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors J. Gen. Virol. 78 1997 445-459
45. C.A. Gerdes M.G. Castro P.R. Lowenstein Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo Mol. Ther. 2 2000 330-338
46. A.E. Morelli et al. Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity J. Gen. Virol. 80 1999 571-583
47. C.E. Thomas G. Schiedner S. Kochanek M.G. Castro P.R. Lowenstein Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases Proc. Natl. Acad. Sci. USA. 97 2000 7482-7487
48. C.E. Thomas D. Birkett I. Anozie M.G. Castro P.R. Lowenstein Acute direct adenoviral vector cytotoxicity and chronic, but not acute, inflammatory responses correlate with decreased vector-mediated transgene expression in the brain Mol. Ther. 3 2001 36-46
49. T. Southgate P. Kingston Gene transfer into neural cells in vivo using adenoviral vectors In: C.R. Gerfen R. McKay M.A. Rogawski D.R. Sibley P. Skolnick (Eds.) Current Protocols in Neuroscience 2000 Wiley New York 4.23.1-4.23.40
50. C. Nyberg-Hoffman E. Aguilar-Cordova Instability of adenoviral vectors during transport and its implication for clinical studies Nat. Med. 5 1999 955-957
51. L.D. Dion J. Fang R.I. Garver Jr. Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus contaminating recombinant adenovirus stocks J. Virol. Methods 56 1996 99-107
52. M. Cotten A. Baker M. Saltik E. Wagner M. Buschle Lipopolysaccharide is a frequent contaminant of plasmid DNA preparations and can be toxic to primary human cells in the presence of adenovirus Gene Ther. 1 1994 239-246
53. C. Maliszewski et al. Dendritic cells in models of tumor immunity. Role Flt3 ligand Pathol. Biol. (Paris) 49 2001 481-483